MAINZ BIOMED B.V. MYNZ 深 沪
等待开盘 10-23 09:30:00 美东时间
1.50
-0.050
-3.23%
华盛通- 最 高1.60
- 今 开1.54
- 成交量 10.84万股
- 最 低 1.47
- 昨 收 1.55
- 总市值 1020.02万
- 52周最高 14.388
- 市盈率 静 --
- 换手率 1.59%
- 52周最低 1.2801
- 委 比 9.94%
- 总股本 680.01万
- 历史最高 1200.00
- 量 比 0.53
- 振 幅 8.39%
- 历史最低 1.2801
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mainz Biomed to Attend 2025 Maxim Growth Summit
Mainz Biomed, a molecular genetics diagnostic company focused on early cancer detection, announced its participation in the 2025 Maxim Growth Summit, scheduled for October 22-23 at The Hard Rock Hotel NYC. The prestigious event will gather industry leaders, innovators, and institutions to discuss latest trends across multiple sectors, featuring keynote speakers Larry Kudlow and Christopher Ruddy, and roundtable discussions with CEOs from small an...
10-15 13:01
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
Mainz Biomed will participate in the World Endoscopy Organization's CRC Screening Committee meeting on October 3, 2025, in Berlin. Dr. Lena Krammes will present findings from the eAArly DETECT study, highlighting RNA-based stool testing's potential in early CRC detection and prevention. The test showed 97% sensitivity and specificity for CRC, 82% for advanced adenomas, and 100% for those with high-grade dysplasia. Mainz Biomed emphasizes its comm...
09-30 12:01
Mainz Biomed Launches ColoAlert Colorectal Cancer Test In Switzerland
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship
09-23 20:08
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Mainz Biomed announced the commercial launch of its colorectal cancer screening product, ColoAlert®, in Switzerland. Key achievements include a partnership with labor team, regulatory approval from Swissmedic, and successful technology transfer enabling local processing. The company is also progressing its eAArly DETECT study, aiming to complete enrollment by year-end 2025.
09-23 12:01
Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official
09-02 20:11
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...
09-02 12:01
Mainz Biomed's ColoAlert Receives Swissmedic Approval, Paving Way For Swiss Launch Of Non-Invasive Colorectal Cancer Test
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal
08-13 20:18
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Mainz Biomed's ColoAlert®, a non-invasive colorectal cancer (CRC) screening test, has received regulatory approval from Swissmedic, allowing its distribution in Switzerland. Targeting individuals aged 50-74, a group of around 2.8 million people, ColoAlert® aims to address the low participation rate in CRC screening programs (below 50%) and support national health goals. The approval follows a partnership with a local Swiss laboratory, enabling br...
08-13 12:01
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of
08-04 22:24
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed announces a $3.0 million follow-on offering of 2,222,222 units at $1.35 per unit, each consisting of one ordinary share or pre-funded warrant and one Series A warrant exercisable at $1.35 per share. The offering, managed by Maxim Group LLC, is set to close on August 5, 2025, pending customary conditions. The securities are registered under SEC's Form F-1 (File No. 333-289095). Investors can obtain the prospectus from Maxim Group.
08-04 14:22
